What are the adverse reactions of Lisocabtagene maraleucel?

Lisocabtagene maraleucel (Lisocabtagene maraleucel), as a cell gene therapy, provides a new treatment option for many patients (non-Hodgkin lymphoma), but it is also accompanied by certain adverse reactions. Patients may experience a variety of side effects that vary in severity and type while using this medication.

First, common side effects include allergic reactions, serious infections, and a weakened immune system. Because the drug affects the function of the immune system, patients are susceptible to infections during treatment. In addition, blood cell counts may decrease during treatment, manifesting as a decrease in neutrophils, red blood cells, or platelets. Decreases in neutrophils, an important infection-fighting white blood cell, may make patients more susceptible to infections, while decreases in red blood cells and platelets may lead to anemia and bleeding risks.

Another significant adverse effect is cytokine release syndrome (CRS), a potentially life-threatening condition. Symptoms of CRS include fever, vomiting, shortness of breath, pain, and hypotension, which may require emergency medical intervention in severe cases. Therefore, it is crucial to monitor patients for changes in symptoms while using lisocabetagen.

In addition, common adverse reactions when using lisocabeta root in patients with follicular lymphoma include headache, musculoskeletal pain, fatigue, constipation, and pyrexia. These adverse reactions may affect patients' quality of life and cause them to feel uncomfortable during treatment.

In conclusion, although lisocabeta root has shown good efficacy in the treatment of certain types of lymphoma, its potential adverse effects cannot be ignored. When using this drug, patients should communicate closely with their doctors and promptly report any symptoms of discomfort so that their doctors can carry out appropriate intervention and management. This is essential to ensure the safety and effectiveness of the treatment process.

Reference materials:https://www.breyanzi.com/